China Pharma (CPHI) vs Werewolf Therapeutics (HOWL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed China Pharma (CPHI) over the past year, losing 51.6% versus a loss of 51.8%. Over five years, HOWL leads with a -94.6% price change compared with -99.7% for CPHI. Werewolf Therapeutics is the larger company by market cap ($44.2 million vs $41.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | HOWL |
|---|---|---|
| Share price | $0.96 | $0.91 |
| Market cap | $41.30M | $44.23M |
| 1-day change | +12.94% | -1.10% |
| YTD return | -20.66% | +43.53% |
| 1-year return | -51.76% | -51.60% |
| 5-year return | -99.65% | -94.61% |
| EPS (TTM) | $-0.42 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.19 | $1.94 |
| 52-week low | $0.38 | $0.27 |
| Distance from 52-week high | -95.00% | -53.02% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +669.23% |
| Average volume | 5.47M | 6.80M |
| Shares outstanding | 43.02M | 48.60M |
| Employees | 215 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Healthcare · Drug Manufacturers - Specialty & Generic · 215 employees
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Healthcare · Biotechnology · 39 employees
CPHI vs HOWL FAQ
Which is bigger, China Pharma or Werewolf Therapeutics?
Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $44.23M compared with $41.30M for China Pharma (CPHI).
Which stock has performed better over the past year, CPHI or HOWL?
HOWL returned -51.60% over the past 12 months, compared with -51.76% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and Werewolf Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for China Pharma and Biotechnology for Werewolf Therapeutics.